Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
Journal: Nature cancer
Published: September 02, 2026
Pregnancy and neonatal outcomes in patients treated for glioma before or during pregnancy: a single-institution retrospective series.
Journal: Journal of neuro-oncology
Published: July 26, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).
Journal: AJNR. American journal of neuroradiology
Published: February 19, 2026
A phase I window-of-opportunity study of neoadjuvant avelumab and hypofractionated radiation therapy in radiation-relapsed meningioma.
Journal: medRxiv : the preprint server for health sciences
Published: October 03, 2025
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.
Journal: Nature communications
Published: September 24, 2025
NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 06, 2025
Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma.
Journal: Current oncology (Toronto, Ont.)
Published: July 25, 2025
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.
Journal: Neuro-oncology advances
Published: July 24, 2025
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas.
Journal: Neuro-oncology
Published: July 14, 2025
Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation.
Journal: Contemporary clinical trials communications
Published: June 20, 2025
Last Updated: 09/26/2026